Compare stocks
Add stockDates End of financial period
| #1 | #2 | #3 | #4 | #5 | #6 | #7 | #8 | |
|---|---|---|---|---|---|---|---|---|
| Remove Idexx Laborator... | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 |
| Remove Stryker Corp | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 |
| Remove TEVA Pharmaceut... | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 |
Profit ROIC / ROE/ROA / ROE / ROA
| #1 | #2 | #3 | #4 | |
|---|---|---|---|---|
| Idexx Laboratories Inc (ROIC) | 60.4% | 56.5% | 54.6% | 52.9% |
| Stryker Corp (ROIC) | 10.7% | 10.0% | 10.8% | 10.6% |
| TEVA Pharmaceutical ... (ROE/ROA) | 28.5% | 33.7% | 29.7% | 25.2% |
Growth Sales and OCF growth / Sales and net income growth
| #1 | #2 | #3 | #4 | |
|---|---|---|---|---|
| Idexx Laboratories Inc | 24.0% | 16.7% | 15.8% | 11.9% |
| Stryker Corp | 11.0% | 14.3% | 13.6% | 15.7% |
| TEVA Pharmaceutical ... | 14.8% | 14.7% | 13.7% | -21.6% |
Payout Shareholder distributions / net income
| #1 | #2 | #3 | #4 | #5 | |
|---|---|---|---|---|---|
| Idexx Laboratories Inc | 109% | 111% | 109% | 105% | 101% |
| Stryker Corp | 37% | 40% | 40% | 39% | 40% |
| TEVA Pharmaceutical ... | 0% | 0% | 0% | 0% | 0% |
Safety Equity/assets and OCF stability / Equity/assets and net income stability
| Balance | Stability | |
|---|---|---|
| Idexx Laboratories Inc | 45.8% | 79.9% |
| Stryker Corp | 48.6% | 86.6% |
| TEVA Pharmaceutical ... | 18.6% | 57.4% |
Price Earnings and FCF yield / Earnings and book yield
| Earnings | FCF / Book | |
|---|---|---|
| Idexx Laboratories Inc | $2.86 | $3.14 |
| Stryker Corp | $3.47 | $4.38 |
| TEVA Pharmaceutical ... | $0.51 | $0.98 |
